Welcome to our dedicated page for Mink Therapeutics news (Ticker: INKT), a resource for investors and traders seeking the latest updates and insights on Mink Therapeutics stock.
MiNK Therapeutics, Inc. reports developments in clinical-stage biopharmaceutical programs built around allogeneic invariant natural killer T cell therapies. Its proprietary iNKT platform is designed to bridge innate and adaptive immunity, with agenT-797 as an off-the-shelf allogeneic iNKT cell therapy evaluated across cancer, immune-mediated disease and pulmonary immune-failure settings.
Company news commonly covers clinical and translational data, scientific-conference presentations, financial results, platform expansion, strategic collaborations and non-dilutive funding tied to iNKT cell therapy programs. Recurring program areas include solid tumors, gastroesophageal cancer, graft-versus-host disease, severe pulmonary inflammation, ARDS or hypoxemic pneumonia, and PRAME-targeted TCR-engineered iNKT approaches for pediatric cancers.
MiNK Therapeutics (NASDAQ: INKT) has dosed the first patient in its randomized Phase 2 trial of agenT-797 plus standard of care vs placebo in severe acute lung injury meeting Global ARDS criteria. The study, authorized in Ukraine and under an active U.S. IND, will assess ICU outcomes such as survival, ventilator-free days, ICU recovery, pathogen control, and immune function, with preliminary data expected in the second half of 2026.
Agenus (Nasdaq: AGEN) reported Phase 2 data for botensilimab (BOT) plus balstilimab (BAL) in advanced checkpoint-refractory cutaneous melanoma (36 patients) to be presented at ASCO 2026.
Median overall survival was 16.6 months, 2‑year survival 42%, and median duration of response was not reached, with 86% of responders in response at 12 months.
Agenus (Nasdaq: AGEN) reported retrospective ASCO 2026 data using Noetik’s AI TARIO-2 platform to analyze routine pretreatment H&E tumor images from 113 patients treated with botensilimab (BOT) plus balstilimab (BAL).
In refractory MSS metastatic colorectal cancer without active liver metastases, an AI-identified subgroup showed a 64% response rate to BOT+BAL versus 9% in the remaining cohort, and significantly better overall survival, with median OS not reached and a hazard ratio of 0.18. TARIO-2 outperformed benchmark pathology foundation models and may support future image-based biomarker strategies for BOT+BAL, subject to prospective validation.
MiNK Therapeutics (NASDAQ: INKT) reported new clinical and translational data on agenT-797, its off-the-shelf allo-iNKT cell therapy, from a critically ill patient treated with sequential Anktiva (N-803) and agenT-797 for unresolving disseminated Coccidioides immitis, ARDS and Pseudomonas pneumonia.
Data showed pathogen suppression, lung immune restoration and tissue repair pathway activation, supporting MiNK’s ongoing randomized Phase 2 trial of agenT-797 plus standard of care in severe acute lung injury and critical illness.
Agenus (Nasdaq: AGEN) reported Phase 1b data for botensilimab + balstilimab in treatment-refractory hepatocellular carcinoma after prior immunotherapy, published in Liver Cancer. The 19-patient cohort included 47% with ALBI grade 2 liver function.
Among 18 efficacy-evaluable patients, the combination showed a 17% ORR (one complete, two partial responses), 50% 18-week CBR, median PFS of 4.4 months, and median OS of 12.3 months. Safety was described as manageable, with no treatment-related deaths and no grade 4 or higher immune-mediated adverse events.
MiNK Therapeutics (NASDAQ: INKT) reported Q1 2026 results and key advances in its allo-iNKT cell therapy platform.
The company initiated a randomized Phase 2 agenT-797 trial in severe acute lung injury/critical illness with preliminary data expected in 2H 2026, expanded non-dilutive collaborations, repaid $5.2M of debt, and ended the quarter with $9.5M in cash and a $2.7M net loss.
MiNK Therapeutics (ticker: INKT) and First Lviv Territorial Medical Union have started a randomized Phase 2 trial of agenT-797, an off-the-shelf allogeneic iNKT cell therapy, in severe acute lung injury (ALI) and hypoxemic respiratory failure.
The placebo-controlled C-1300-02 study, authorized by Ukraine’s Ministry of Health and supported by an active U.S. IND, will assess survival, ventilator-free days, ICU recovery, pathogen control, and secondary infections. Expansion to U.S. sites is underway, with preliminary data expected in the second half of 2026.
MiNK Therapeutics (NASDAQ: INKT) reported ASGCT 2026 data on its off-the-shelf iNKT therapy agenT-797, showing context-dependent immune responses from the same donor batch without genetic engineering.
In 34 solid tumor patients it induced TH1 IFN-gamma elevation; in 20 ARDS patients it induced TH2 IL-4/IL-13 elevation, with associated clinical responses and a favorable safety profile, supporting advancement to a randomized Phase 2 acute lung injury trial with preliminary data expected in 2026.
Agenus (Nasdaq: AGEN) reported Q1 2026 results and key BOT+BAL milestones. Total revenue was $33.7M (vs $24.1M Q1 2025), with net income of $39.2M (vs $(26.4)M loss). Cash was $35.0M at March 31, 2026.
BOT+BAL advanced into Phase 3 BATTMAN enrollment, authorized access expanded globally, and the $91M Zydus collaboration closed, adding capital and U.S. manufacturing capacity. The SEC investigation concluded with no enforcement action, and a related securities class action was dismissed.
MiNK Therapeutics (NASDAQ: INKT) will report first quarter 2026 financial results for the period ended March 31, 2026, before market open on May 15, 2026. A conference call and webcast will be held at 8:30 AM ET to review results and provide a corporate update.
The update will cover progress across the iNKT cell therapy platform, including clinical development, translational research, platform expansion, strategic initiatives, continued advancement of lead allo-iNKT therapy agenT-797, recent scientific presentations, and a collaboration with C-Further on a PRAME-targeted, TCR-engineered iNKT cell therapy for pediatric cancers. A live webcast and replay will be available on the company website.